CDKN1A and ovarian carcinoma: The lncRNA promoter of CDKN1A antisense DNA-damage-activated RNA (PANDAR) has been reported to serve as a negative regulator of cisplatin sensitivity, and cisplatin has been shown to induce higher levels of PANDAR than doxorubicin or paclitaxel in human ovarian cancer cells [41].